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Mycosis fungoides (MF), the most common form
of cutaneous T-cell lymphoma, is composed of
skin-homing mature effector T lymphocytes.1
Limited patch or plaque disease generally follows
an indolent course with little, if any, effect on
overall survival; therefore, skin-directed therapies
are preferred and include corticosteroids, nitrogen
mustard, phototherapy, and radiotherapy.2 Systemic
interferon alfa has long been used in the treatment of
more generalized disease by enhancing cytotoxic
helper T cell (Th)1 lymphocyte and natural killer cell
responses and suppressing Th2 differentiation, but is
not used for limited disease secondary to its
side-effect profile and method of administration.3
Imiquimod is a topical immunomodulator that stim-
ulates a Th1 response through activation of toll-like
receptor 7 on plasmacytoid dendritic cells, leading to
production of interferon alpha, tumor necrosis
factor alfa, and interleukin-12.4 Production of this
cytotoxic cytokine milieu is thought to be the driving
force in the treatment of condyloma, molluscum
contagiosum, superficial basal cell carcinomas, len-
tigo maligna, and cutaneous lymphomas.5 Several
reportswerepublishedon the effectiveness of topical
imiquimod in early-stage MF.6,7 We present 2 cases
highlighting the effectiveness of topical imiquimod
in the treatment of folliculotropic and tumor MF.
CASE 1
Awoman in her 80s with a 15-year history of stage
IB MF presented to the dermatology clinic for a 6-
year history of progressive involvement of the
periocular skin, despite prior use of class I topical
corticosteroids, topical carmustine, topical bexaro-
tene, psoralen plus ultraviolet A, and systemicthe Department of Dermatology, Mayo Clinic.
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ayo.edu.methotrexate. Physical examination found infiltrated
plaques involving the left upper and lower eyelids
and right nasal sidewall with variable alopecia (Fig 1,
A). Biopsies confirmed MF with follicular involve-
ment (folliculotropic MF). Localized radiotherapy
had been proposed, but we recommended a trial
of monotherapy with topical imiquimod 5% cream.
Treatment was initiated at twice weekly and titrated
to 3 times weekly, which resulted in complete
clinical clearance after 6 months of treatment.
During therapy, she reported a mildly symptomatic
erythema at the sites of application that occurred
primarily during the first several weeks of initiating
treatment. No other adverse effects were reported.
Recurrence has not developed at these sites for
10 months (Fig 1, B), but new lesions developed in
previously noninvolved sites that have responded
similarly with topical imiquimod monotherapy.
CASE 2
A white man in his 60s with a 4-year history of
nummular dermatitis, previously controlled with
topical betamethasone and occasional oral predni-
sone tapers, presented with a progressive indurated
plaque on the right ankle. Punch biopsies found an
atypical dermal lymphocytic infiltrate with variable
epidermotropism. Biopsies of the other grossly
eczematous plaques on the lower extremities
confirmed subacute dermatitis with rare eosinophils.
Peripheral blood flow cytometry was unremarkable,
and a diagnosis of stage IBMFwasmade. OnemonthJAAD Case Reports 2015;1:348-50.
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Fig 2. A, Patient 2 with indurated eroded plaque of the
right ankle with new-onset tumor. B, Same patient after
2 months of topical imiquimod.
Fig 1. A, Patient 1 with infiltrated plaques of the left upper
and lower eyelid and right nasal sidewall with variable
alopecia. B, Same patient 1 year later after 6 months of
topical imiquimod. Subtle hypopigmentation in areas of
prior involvement is present.
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dermatitis but did not clear the mycosis fungoides.
Despite the addition of narrow-band ultraviolet B
phototherapy 3 times a week, the plaque ulcerated
and a tumor developed (Fig 2, A). A repeat 4-mm
punch biopsy confirmed tumor MF but, the result
was negative for large cell transformation. Topical
steroids and phototherapy were then discontinued,
and a trial of topical imiquimod 5% cream as
monotherapy was initiated once daily, 5 days a
week. A brisk inflammatory response developed
and cleared after 2 months of therapy (Fig 2, B).
This treatment site has remained clear for 9 months,
although the patient subsequently had new dyshi-
drotic papules elsewhere on the foot that showed an
atypical epidermotropic T-cell infiltrate clonally
identical to the presenting ankle lesion. This vesic-
ular MF was also treated with a second course of
imiquimod, once daily for 5 days a week, with
complete clearance after 3 months of therapy.
DISCUSSION
We describe 2 cases of topical imiquimod 5%
cream causing complete clinical clearance of MF
subsets that traditionally have been refractive to
conventional therapies.8 Case 1 highlights the use
of imiquimod as monotherapy in folliculotropic MF
lesions in a difficult-to-treat area, without the risk of
skin atrophy associated with topical corticosteroid
use. Case 2 highlights imiquimod as an effective
therapy in a case of plaque disease with tumoralprogression to stage IIB MF otherwise refractory to
topical corticosteroids and narrowband ultraviolet B
phototherapy. Later new-onset vesicular MF also
responded to imiquimod treatment. In both cases,
imiquimod was well tolerated, with macular ery-
thema noted within 2 weeks of initiation of therapy,
and maintenance therapy was not required after
resolution of the lesions. Clearance of the folliculo-
tropic MF was comparatively slower than for the
tumor MF.
Application site reactions similar to those reported
for treatment of nonmelanoma skin cancers should
be expected, including erythema, scabbing, erosion,
edema, and possibly ulceration with accompanying
itching, pain, and burning especially with longer
term use.8 These signs and symptoms reflect the
suspected mechanism of activation of the immune
system. In our experience, the frequency of appli-
cation must be titrated for each patient to achieve the
desired localized cutaneous reaction. If imiquimod is
not applied at the necessary frequency, and patients
do not have the expected inflammatory response, it
is less likely to have an adequate response to
therapy. Compared with a prior series using 5%
imiquimod cream in the treatment of patch/plaque
MF, the treatment duration in these cases was longer
and/or imiquimod application more frequent, which
may explain the higher response rate.9
In this series of 2 patients, imiquimod was a safe,
well-tolerated, and effective skin-directed therapy
for skin-limited MF. Our cases highlight its potential
value in limited tumor stage and folliculotropic
disease.
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